AR074860A1 - Derivados de pirimidina y sus metodos de uso - Google Patents

Derivados de pirimidina y sus metodos de uso

Info

Publication number
AR074860A1
AR074860A1 ARP090105056A ARP090105056A AR074860A1 AR 074860 A1 AR074860 A1 AR 074860A1 AR P090105056 A ARP090105056 A AR P090105056A AR P090105056 A ARP090105056 A AR P090105056A AR 074860 A1 AR074860 A1 AR 074860A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
haloalkyl
occurrence
methods
Prior art date
Application number
ARP090105056A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR074860A1 publication Critical patent/AR074860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

Composiciones que comprenden un derivado de pirimidina y métodos de uso de los derivados de pirimidina para tratar o prevenir obesidad, diabetes, una complicación diabática, un trastorno metabólico, una enfermedad cardiovascular o un trastorno relacionado con la actividad de un receptor acoplado a proteína G (GPCR) en un paciente. Reivindicación 1: Un compuesto que tiene la fórmula (1): o una de sus sales, solvatos, ésteres o prodrogas farmacéuticamente aceptables, en donde: R1 es H, alquilo, halo u -O-alquilo; R2a es H o alquilo o R2a y R2b se unen para formar -CH2CH2-, -CH2CH2CH2- o -CH2OCH2-; R2b es H o alquilo; R3a es H o alquilo o R3a y R3b se unen para formar -CH2CH2-, -CH2CH2CH2- o -CH2OCH2-; R3b es H o alquilo; R4 es alquilo, cicloalquilo, haloalquilo, arilo, -alquilen-arilo o heteroarilo, en donde un grupo arilo o heteroarilo puede estar opcionalmente sustituido con uno o varios grupos, que pueden ser iguales o diferentes y están seleccionados de alquilo, halo, haloalquilo, -O-alquilo, -CN y -S(O)2-alquilo; R5 es alquilo, cicloalquilo, haloalquilo, -alquilen-arilo, alquenilo o -N(alquilo)2; R6 es H o alquilo; A es un enlace cuando Q es -N- y A es -N(R6)- cuando Q es -CH-; Q es-N- o -CH-; W es -C(O)-, -C(O)O- o -S(O)2; Y es -O-, -S-, -NH- o -CH2- cuando Z es -CH- e Y es un enlace cuando Z es -N-; Z es -CH- o -N-; cada aparición de n es, de modo independiente, 0, 1 ó 2; y cada aparición de p es 0, 1 ó 2, de modo que, cuando Q y Z son ambos -N-, luego cada aparición de p es 1 ó 2.
ARP090105056A 2008-12-23 2009-12-22 Derivados de pirimidina y sus metodos de uso AR074860A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14014908P 2008-12-23 2008-12-23

Publications (1)

Publication Number Publication Date
AR074860A1 true AR074860A1 (es) 2011-02-16

Family

ID=41698138

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090105056A AR074860A1 (es) 2008-12-23 2009-12-22 Derivados de pirimidina y sus metodos de uso

Country Status (8)

Country Link
US (1) US8722882B2 (es)
EP (1) EP2382204B1 (es)
JP (1) JP2012513469A (es)
AR (1) AR074860A1 (es)
AU (1) AU2009330206A1 (es)
CA (1) CA2747807A1 (es)
TW (1) TW201035073A (es)
WO (1) WO2010075269A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009330208A1 (en) * 2008-12-23 2011-08-04 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EP2503891B1 (en) * 2009-11-23 2016-08-03 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2569302A1 (en) * 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
JP6463631B2 (ja) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Ｇｐｒ−１１９のモジュレータとしての新規化合物
US10227406B2 (en) 2013-06-26 2019-03-12 Amgen, Inc Cannabinoid receptor-1 (CB1) monoclonal antibodies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
EP0179904A1 (en) 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
SK285695B6 (sk) 1997-05-14 2007-06-07 Atherogenics, Inc. Použitie monoester probukolu s kyselinou jantárovou na liečenie kardiovaskulárnych a zápalových ochorení
EP1932535A3 (en) 1998-07-31 2008-10-29 Novo Nordisk A/S Stimulation of beta cell profileration
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
CN1342090A (zh) 1998-12-23 2002-03-27 G·D·瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
FR2802817B1 (fr) 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
JP3438186B2 (ja) 2000-12-01 2003-08-18 山之内製薬株式会社 糖尿病治療剤スクリーニング方法
JP2002185490A (ja) 2000-12-19 2002-06-28 Denso Corp 通信システム及び端末装置
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004076413A2 (en) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
MXPA06014129A (es) 2004-06-04 2007-03-07 Arena Pharm Inc Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos.
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
EP2503891B1 (en) 2009-11-23 2016-08-03 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof

Also Published As

Publication number Publication date
JP2012513469A (ja) 2012-06-14
CA2747807A1 (en) 2010-07-01
EP2382204A1 (en) 2011-11-02
US8722882B2 (en) 2014-05-13
TW201035073A (en) 2010-10-01
US20110263570A1 (en) 2011-10-27
EP2382204B1 (en) 2018-07-11
WO2010075269A1 (en) 2010-07-01
AU2009330206A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
AR074860A1 (es) Derivados de pirimidina y sus metodos de uso
AR071207A1 (es) Derivados de benzofurano, benzotiazol y/o benzotiofeno moduladores de receptores farnesoides fxr, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos como para tratar dislipemias, obesidad y diabetes, entre otras enfermedades.
HRP20191579T1 (hr) Spojevi kao modulatori za ror gama
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
PE20130774A1 (es) Compuestos heterociclicos activadores de ampk y metodos para emplearlos
AR066659A1 (es) Derivados de espiroindolinona
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
AR068098A1 (es) Derivados de ciclopentandiona como herbicidas
AR066107A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen.
AR061667A1 (es) Arilamidas sustituidas con tetrazol
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
AR085149A1 (es) Moduladores del receptor de glucagon
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
AR086881A1 (es) Derivados de picolinamida como agonistas del receptor cb2
NO20082917L (no) Oksadiazolderivater med CRTH2-reseptoraktivitet
AR071739A1 (es) Inhibidores de transcriptasa reversa
CO6251283A2 (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
AR087494A1 (es) Derivados de isoxazolina como compuestos insecticidas
MY170822A (en) Ethynyl derivatives as mglur5 allosteric modulators
NO20071112L (no) Nye heterosykliske karboksylsyreamidderivater
AR084913A1 (es) Derivados de aril-benzocicloalquil-amida
AR073142A1 (es) Inhibidores de quinasa tipo polo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal